| 13.1385 -0.092 (-0.69%) | 05-29 13:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.2 | 1-year : | 18.6 |
| Resists | First : | 14.73 | Second : | 15.93 |
| Pivot price | 13.88 |
|||
| Supports | First : | 12.8 | Second : | 10.64 |
| MAs | MA(5) : | 13.41 |
MA(20) : | 14.09 |
| MA(100) : | 13.59 |
MA(250) : | 11.43  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 8.3 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 17.14 | Low : | 5.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ENTA ] has closed above bottom band by 23.5%. Bollinger Bands are 10.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.46 - 13.53 | 13.53 - 13.6 |
| Low: | 12.96 - 13.03 | 13.03 - 13.1 |
| Close: | 13.12 - 13.23 | 13.23 - 13.34 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Thu, 28 May 2026
Enanta Pharmaceuticals Advances RSV Treatment and Immunology Pipeline - GuruFocus
Thu, 28 May 2026
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
Tue, 19 May 2026
Enanta Pharma's RSV Bet And Immunology Ambitions - RTTNews
Thu, 14 May 2026
Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives - simplywall.st
Wed, 13 May 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Tue, 12 May 2026
Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 92.8 (%) |
| Shares Short | 2,160 (K) |
| Shares Short P.Month | 2,130 (K) |
| EPS | -2.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.36 |
| Profit Margin | -89.6 % |
| Operating Margin | -69.1 % |
| Return on Assets (ttm) | -11.9 % |
| Return on Equity (ttm) | -59 % |
| Qtrly Rev. Growth | 15 % |
| Gross Profit (p.s.) | 2.37 |
| Sales Per Share | 2.37 |
| EBITDA (p.s.) | -1.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -5.06 |
| PEG Ratio | 0 |
| Price to Book value | 3.01 |
| Price to Sales | 5.52 |
| Price to Cash Flow | -48.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|